XML 67 R54.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborations and Licensing Arrangements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 29, 2019
Dec. 30, 2016
May 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Oct. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized from collaborations and services       $ 17,448,000 $ 3,465,000    
Deferred revenue - current       32,384,000   $ 36,885,000  
Deferred revenue - long term       15,867,000   10,680,000  
Collaboration and License Agreement | Receptor              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue       400,000      
Deferred revenue - current       300,000      
Nonrefundable option exercise and license fee   $ 1,000,000          
Collaboration and License Agreement | United Therapeutics Corporation              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Upfront payment received             $ 45,000,000
Milestone Payment Received $ 12,500,000            
Revenue recognized from collaborations and services       7,600,000      
Deferred revenue       43,500,000      
Deferred revenue - current       30,500,000      
Deferred revenue - long term       13,000,000      
Total transaction price       97,500,000      
Collaboration and License Agreement | United Therapeutics Corporation | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Potential milestone payments to be receive       37,500,000      
Additional option exercise and development milestone payments to be receive       40,000,000      
Research Agreement | United Therapeutics Corporation              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Upfront payment received           10,000,000  
Revenue recognized from collaborations and services       4,700,000      
Deferred revenue       1,600,000      
Total transaction price       10,000,000      
Research Agreement | United Therapeutics Corporation | Product Prototype              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price       $ 9,000,000      
Revenue performance obligation, method used       The revenue for the product prototype is recognized using an output method (based on project milestones achieved and surveys of performance completed to date). The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation.      
Research Agreement | United Therapeutics Corporation | Engineering Consulting Services              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price       $ 1,000,000      
Revenue performance obligation, method used       The revenue for the engineering consulting services is recognized using a ratable method until the obligation is satisfied and the Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation.      
Research Agreement | United Therapeutics Corporation | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Potential milestone payments to be receive       $ 30,000,000      
License and Distribution Agreement | Foreign Country | India Tax Authority              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Income Taxes Paid           $ 200,000  
License and Distribution Agreement | Cipla Ltd              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue       2,100,000      
Deferred revenue - current       $ 200,000      
Marketing and distribution agreement date     2018-05